

# BRISTOL-MYERS SQUIBB CO.

ISIN: US1101221083 WKN: 110122108 Asset Class: Stock



## Company Profile

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures              | 2023           |                        | 2022           |                        | 2021            |                        |
|--------------------------------|----------------|------------------------|----------------|------------------------|-----------------|------------------------|
|                                | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets          | Liabilities and equity |
| Current assets                 | 31,770,000,000 |                        | 27,273,000,000 |                        | 33,262,000,000  |                        |
| Common stock capital           |                | 292,000,000            |                | 292,000,000            |                 | 292,000,000            |
| Fixed assets                   | 63,389,000,000 |                        | 69,547,000,000 |                        | 76,052,000,000  |                        |
| Equity capital of a company    |                | 29,485,000,000         |                | 31,118,000,000         |                 | 36,006,000,000         |
| Cash and cash equivalents      | 11,519,000,000 |                        | 9,271,000,000  |                        | 14,119,000,000  |                        |
| Accrued liabilities            |                | 480,000,000            |                | 402,000,000            |                 | 654,000,000            |
| Other assets                   | -              |                        | -              |                        | -               |                        |
| Current liabilities            |                | 22,262,000,000         |                | 21,890,000,000         |                 | 21,868,000,000         |
| Prepayments and accrued income | -              |                        | -              |                        | -               |                        |
| Non-current liabilities        |                | 43,412,000,000         |                | 43,812,000,000         |                 | 51,440,000,000         |
| Different income               |                | -                      |                | -                      |                 | -                      |
| Other liabilities              |                | 4,411,000,000          |                | 4,927,000,000          |                 | 5,806,000,000          |
| Total assets                   | 95,159,000,000 | 95,159,000,000         | 96,820,000,000 | 96,820,000,000         | 109,314,000,000 | 109,314,000,000        |

## Balance notes

|                     | 2023    | 2022    | 2021    |
|---------------------|---------|---------|---------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees           | 34,100  | 34,300  | 32,200  |
| Equity ratio        | 31.04%  | 32.20%  | 32.99%  |
| Debt-equity ratio   | 222.14% | 210.57% | 203.09% |

## Others

|                  | 2023  | 2022   | 2021   |
|------------------|-------|--------|--------|
| Tax Expense Rate | 4.74% | 17.74% | 13.39% |

# BRISTOL-MYERS SQUIBB CO.

ISIN: US1101221083 WKN: 110122108 Asset Class: Stock

## Income statement

|   | 2023           | 2022           | 2021           |
|---|----------------|----------------|----------------|
| Turnover  | 45,006,000,000 | 46,159,000,000 | 46,385,000,000 |
| Net income  | 8,025,000,000  | 6,327,000,000  | 6,994,000,000  |
| EBIT  | 8,585,603,200  | 8,226,502,400  | 8,806,876,800  |
| Operating income before taxes                                 | 8,440,000,000  | 7,713,000,000  | 8,098,000,000  |
| Cash Flow   | 13,860,000,000 | 13,066,000,000 | 16,207,000,000 |
| Net interest income   | -717,000,000   | -1,061,000,000 | -1,295,000,000 |
| Research and development expenses                             | 9,207,000,000  | 9,411,000,000  | 9,533,000,000  |
| Income taxes  | 400,000,000    | 1,368,000,000  | 1,084,000,000  |
| Result from investments in subsidiaries, associates and other | -              | -              | -              |
| Revenues per employee   | 1,237,467      | 1,261,769      | 1,350,639      |

## Board of Directors

## Members of Management Board

|                       |                               |
|-----------------------|-------------------------------|
| Deepak Bhatt          | Member of Board of Directors  |
| Julia Haller          | Member of Board of Directors  |
| Karen Vousden         | Member of Board of Directors  |
| Manuel Hidalgo Medina | Member of Board of Directors  |
| Derica Rice           | Member of Board of Directors  |
| Gerald Storch         | Member of Board of Directors  |
| Paula Price           | Member of Board of Directors  |
| Peter Arduini         | Member of Board of Directors  |
| Phyllis Yale          | Member of Board of Directors  |
| Theodore Samuels      | Member of Board of Directors  |
| Chris Boerner         | Chairman of Managing Board    |
| Adam Lenkowsky        | Member of Executive Committee |
| Amanda Poole          | Member of Executive Committee |
| Cari Gallman          | Member of Executive Committee |
| David Elkins          | Member of Executive Committee |
| Greg Meyers           | Member of Executive Committee |
| Karin Shanahan        | Member of Executive Committee |
| Kim Jablonski         | Member of Executive Committee |
| Lynelle B. Hoch       | Member of Executive Committee |
| Pamela Fisher         | Member of Executive Committee |
| Peter S. Paine III    | Member of Executive Committee |
| Robert Plenge         | Member of Executive Committee |
| Samit Hirawat         | Member of Executive Committee |
| Sandra Leung          | Member of Executive Committee |